Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel D'Incan

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Science Translational Medicine|March 8, 2013
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell responseNatacha Colliou, Damien Picard, Frédérique Caillot, et al.
Haematologica|November 12, 2013
Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous LymphomasAdèle de Masson, Marie Beylot-Barry, Jean-David Bouaziz, et al.
The Journal of Investigative Dermatology|December 14, 2018
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General PopulationMarthe Plaquevent, Florence Tétart, Laurence Fardet, et al.
Archives of Dermatology|July 18, 2012
Prognostic factors of paraneoplastic pemphigusSandy Leger, Damien Picard, Saskia Ingen-Housz-Oro, et al.
The British Journal of Dermatology|August 12, 2024
Pustular mycosis fungoides has a poor outcome: a multicentric clinicopathological and molecular case seriesChristophe Bontoux, Marine Badrignans, Sivem Afach, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
JAMA Dermatology|March 19, 2020
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical TrialClaire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 21, 2023
Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationisNadège Cordel, Jasmine Flament, Fabienne Jouen, et al.
Blood|February 7, 2020
Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedemaThibault Mahévas, Bertrand Arnulf, Jean-David Bouaziz, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Science Translational Medicine|March 8, 2013
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell responseNatacha Colliou, Damien Picard, Frédérique Caillot, et al.
Haematologica|November 12, 2013
Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous LymphomasAdèle de Masson, Marie Beylot-Barry, Jean-David Bouaziz, et al.
The Journal of Investigative Dermatology|December 14, 2018
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General PopulationMarthe Plaquevent, Florence Tétart, Laurence Fardet, et al.
Archives of Dermatology|July 18, 2012
Prognostic factors of paraneoplastic pemphigusSandy Leger, Damien Picard, Saskia Ingen-Housz-Oro, et al.
The British Journal of Dermatology|August 12, 2024
Pustular mycosis fungoides has a poor outcome: a multicentric clinicopathological and molecular case seriesChristophe Bontoux, Marine Badrignans, Sivem Afach, et al.
Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.
JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.
JAMA Dermatology|March 19, 2020
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical TrialClaire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 21, 2023
Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationisNadège Cordel, Jasmine Flament, Fabienne Jouen, et al.
Blood|February 7, 2020
Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedemaThibault Mahévas, Bertrand Arnulf, Jean-David Bouaziz, et al.
Pageof 8